| JNPMEDI selected for Unicorn Bridge in recognition of its innovation and growth potential
| Two years of government funding and global expansion support to accelerate entry into the global clinical trial market
| Selection follows DIPS, further validating JNPMEDI’s AI deep-tech competitiveness
JNPMEDI, an AI-powered clinical development consulting company for pharmaceuticals and innovative medical devices, announced on July 8 that it had been selected for the Ministry of SMEs and Startups’ 2026 Unicorn Bridge program.
Launched this year, Unicorn Bridge is a government support program aimed at identifying promising deep-tech companies with proven innovation and growth potential and helping them grow into globally competitive unicorns valued at more than KRW 1 trillion. The 50 selected companies will receive up to KRW 1.6 billion in government funding over two years and up to KRW 20 billion in special guarantees from the Korea Technology Finance Corporation. They will also be offered tailored support for global fundraising, entry into public-sector markets, and the establishment of overseas offices. The selected companies have an average enterprise value of approximately KRW 180.1 billion and average revenue of KRW 24.4 billion.
JNPMEDI applied to the program with its technology for advancing an integrated AI-powered platform for global clinical trial design, operations, and data standardization. In the highly competitive program, known for its rigorous assessment of technology and growth potential, the company was named among the final 50 participants in recognition of its differentiated capabilities and future growth potential in clinical trial and pharmaceutical and biotech R&D data management.
The selection follows JNPMEDI’s inclusion in the Ministry’s 2026 Deep Tech Incubator Project for Startups, or DIPS. The consecutive selections are significant in that they further recognize the company’s technological innovation and core capabilities for global expansion and growth. They also reaffirm JNPMEDI’s competitiveness as a global life sciences RDC, or Research, Development, and Commercialization, company.
JNPMEDI provides Maven Clinical Cloud, a SaaS-based platform for clinical trial data management and operations. Through the platform, the company supports pharmaceutical and biotech companies in Korea and overseas across the full clinical development lifecycle, from clinical strategy and trial operations to data collection, management, and regulatory support.
Going forward, JNPMEDI plans to actively use Unicorn Bridge funding and follow-up programs, including global investor relations opportunities and overseas expansion support. The company aims to build an innovative platform that improves R&D productivity and strengthens clinical trial execution capabilities for pharmaceutical and biotech companies, accelerating its growth toward unicorn status.
Kwunho Jeong, CEO of JNPMEDI, said, “Being selected for Unicorn Bridge, which applies rigorous standards to technological capability and innovation, is recognition of our proprietary technology and potential as a next-generation unicorn.”
“Building on the government’s support, we will establish JNPMEDI as a company leading the future of global clinical trials,” he added.
| JNPMEDI selected for Unicorn Bridge in recognition of its innovation and growth potential
| Two years of government funding and global expansion support to accelerate entry into the global clinical trial market
| Selection follows DIPS, further validating JNPMEDI’s AI deep-tech competitiveness
JNPMEDI, an AI-powered clinical development consulting company for pharmaceuticals and innovative medical devices, announced on July 8 that it had been selected for the Ministry of SMEs and Startups’ 2026 Unicorn Bridge program.
Launched this year, Unicorn Bridge is a government support program aimed at identifying promising deep-tech companies with proven innovation and growth potential and helping them grow into globally competitive unicorns valued at more than KRW 1 trillion. The 50 selected companies will receive up to KRW 1.6 billion in government funding over two years and up to KRW 20 billion in special guarantees from the Korea Technology Finance Corporation. They will also be offered tailored support for global fundraising, entry into public-sector markets, and the establishment of overseas offices. The selected companies have an average enterprise value of approximately KRW 180.1 billion and average revenue of KRW 24.4 billion.
JNPMEDI applied to the program with its technology for advancing an integrated AI-powered platform for global clinical trial design, operations, and data standardization. In the highly competitive program, known for its rigorous assessment of technology and growth potential, the company was named among the final 50 participants in recognition of its differentiated capabilities and future growth potential in clinical trial and pharmaceutical and biotech R&D data management.
The selection follows JNPMEDI’s inclusion in the Ministry’s 2026 Deep Tech Incubator Project for Startups, or DIPS. The consecutive selections are significant in that they further recognize the company’s technological innovation and core capabilities for global expansion and growth. They also reaffirm JNPMEDI’s competitiveness as a global life sciences RDC, or Research, Development, and Commercialization, company.
JNPMEDI provides Maven Clinical Cloud, a SaaS-based platform for clinical trial data management and operations. Through the platform, the company supports pharmaceutical and biotech companies in Korea and overseas across the full clinical development lifecycle, from clinical strategy and trial operations to data collection, management, and regulatory support.
Going forward, JNPMEDI plans to actively use Unicorn Bridge funding and follow-up programs, including global investor relations opportunities and overseas expansion support. The company aims to build an innovative platform that improves R&D productivity and strengthens clinical trial execution capabilities for pharmaceutical and biotech companies, accelerating its growth toward unicorn status.
Kwunho Jeong, CEO of JNPMEDI, said, “Being selected for Unicorn Bridge, which applies rigorous standards to technological capability and innovation, is recognition of our proprietary technology and potential as a next-generation unicorn.”
“Building on the government’s support, we will establish JNPMEDI as a company leading the future of global clinical trials,” he added.